Roupen Odabashian: We should have a universal test to screen for many cancers at once
Roupen Odabashian shared on LinkedIn:
“Every cancer should have a screening test, or let’s put it another way: we should have a universal, cheap, and accessible test to screen for many cancers at once.
This article highlights how cancer screening is falling behind the average in rural areas. People in these areas have less access to care, which makes things even worse.
Unfortunately, no pharmaceutical company will spend billions of dollars on improving screening in these rural areas, but they will spend billions on developing drugs that help with advanced stages of cancer.
Cancer screening is broken.” .
Read further.
Source: Roupen Odabashian/LinkedIn
Dr. Roupen Odabashian is an accomplished Internal Medicine Physician and Hematology/Oncology Fellow with a profound commitment to advancing healthcare through clinical practice, research, and technology.
Currently based at the prestigious Karmanos Cancer Institute, Dr. Odabashian is actively involved in pioneering cancer treatments and conducting clinical research.
In addition to his clinical work, Dr. Odabashian is a multifaceted healthcare professional. He hosts podcast at OncoDaily, engaging with leading experts in oncology to share valuable insights with the medical community.
Dr. Odabashian also contributes his expertise as an advisor at Spiraldot Health and Mesh AI, supporting innovative ventures in healthcare technology and collaborative scheduling to combat clinician burnout.
With his diverse roles and unwavering dedication, Dr. Odabashian exemplifies a commitment to driving positive change in healthcare.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023